Publications by authors named "F Manfredi"
Acute myeloid leukemia (AML) derives from hematopoietic stem and progenitor cells (HSPCs). To date, no AML-exclusive, non-HSPC-expressed cell-surface target molecules for AML selective immunotherapy have been identified. Therefore, to still apply surface-directed immunotherapy in this disease setting, time-limited combined immune-targeting of AML cells and healthy HSPCs, followed by hematopoietic stem cell transplantation (HSCT), might be a viable therapeutic approach.
View Article and Find Full Text PDFWe previously developed an innovative strategy to induce CD8 T lymphocyte-immunity through in vivo engineering of extracellular vesicles (EVs). This approach relies on intramuscular injection of DNA expressing antigens of interest fused at a biologically-inactive HIV-1 Nef protein mutant (Nef). Nef is very efficiently incorporated into EVs, thus conveying large amounts of fusion proteins into EVs released by transfected cells.
View Article and Find Full Text PDFArticle Synopsis
- CAR T-cell therapies targeting specific antigens have been approved for treating B- and plasma-cell cancers, but their efficacy is limited by low antigen expression and safety issues due to the lack of control over their activity.
- A new approach, called adaptor-CAR (AdFITC-CAR) T-cells, was developed to target a broader range of AML antigens and allow for modulation of T-cell activity, potentially avoiding damage to healthy cells.
- Experiments showed that AdFITC-CAR T-cells, especially when combined with multiple adaptor proteins, significantly improved the killing of AML cells and demonstrated effective therapy in mouse models, suggesting a promising advance in treating AML.
Despite the efforts to identify fluid biomarkers to improve diagnosis of Frontotemporal dementia (FTD), only a few candidates have been described in recent years. In a previous study, we identified three circulating miRNAs (miR-92a-3p, miR-320a and miR-320b) differentially expressed in FTD patients with respect to healthy controls and/or Alzheimer's disease (AD) patients. Now, we investigated whether those changes could be due to miRNAs contained in neuron-derived extracellular vesicles (NDEVs).
View Article and Find Full Text PDFThe longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.
Front Immunol
August 2024
Introduction: SARS-CoV-2 pandemic still poses a significant burden on global health and economy, especially for symptoms persisting beyond the acute disease. COVID-19 manifests with various degrees of severity and the identification of early biomarkers capable of stratifying patient based on risk of progression could allow tailored treatments.
Methods: We longitudinally analyzed 67 patients, classified according to a WHO ordinal scale as having Mild, Moderate, or Severe COVID-19.